Clinical laboratories act at the frontline of identification of infections caused by multidrug-resistant organisms, and yet the tools they apply are often woefully out of date. Incomplete adoption of current testing standards, updated breakpoints, and tests for new drugs across laboratories has been exacerbated by lack of coordination between standards development organizations (SDOs), pharmaceutical companies, susceptibility test manufacturers, and the US Food and Drug Administration. The 21st Century Cures Act includes provisions to enable alignment between these groups by (1) allowing recognition of breakpoints set by qualified SDOs; (2) publicly posting recognized breakpoints; and (3) reviewing breakpoints for necessary updates, every 6 months. Combined, these provisions will ensure more rapid recognition of current breakpoints, improving detection and management of resistant infections. Although several limitations remain, this will ultimately allow susceptibility test manufacturers to more readily update to current breakpoints.
There is no question that antimicrobial resistance is one of the most pressing medical issues of the 21st century. The World Health Organization has designated antimicrobial resistance as one of the biggest threats to global health, food security, and development [1] . Especially concerning is the emergence of multidrug resistance among gram-negative bacteria. In the past decade, carbapenemase-producing Enterobacteriaceae and pan-resistant Acinetobacter baumannii and Pseudomonas aeruginosa have become endemic in many regions globally, including the United States [2, 3] . Treatment of infections with multidrug-resistant (MDR) gram-negative bacteria often requires clinicians to resort to using older, toxic antimicrobial agents [4] [5] [6] . Recent emphasis has been placed on development of antimicrobial agents to combat these highly resistant bacteria, but new agents do not address all emerging resistance mechanisms, and these drugs are not widely available to patients around the globe, including in areas where MDR gram-negative bacteria are most prevalent [7] .
On the frontline of confronting antimicrobial resistance is the clinical microbiology laboratory, where isolates with novel, unusual, or concerning resistance patterns are first encountered.
Identification of drug-resistant pathogens in US clinical microbiology laboratories is primarily accomplished using commercial antimicrobial susceptibility test systems (cASTs) that generate minimum inhibitory concentration (MICs) values.
A breakpoint is applied to each MIC, which is then interpreted as susceptible, intermediate, or resistant [8] . In a previous article, we summarized challenges faced by clinical laboratories to reliably detect antimicrobial resistance when using cASTs [9] . These include (1) restrictions enforced by the US Food and Drug Administration (FDA) that prohibit clearance of cASTs for antimicrobials with off-label organisms; (2) updated interpretive criteria (breakpoints) established by the Clinical and Laboratory Standards Institute (CLSI) that are not available on all cASTs; and (3) approval of new antimicrobial agents with no or few corresponding cASTs. Combined, these factors have led to a variety of susceptibility testing practices used by clinical microbiology laboratories in the United States, with incomplete adoption of updated breakpoints and tests for new drugs [9] . At best, some laboratories have modified their cASTs for use off-label with current breakpoints, and test new agents using manual methods. At worst, many laboratories are using breakpoints that have been out of date for nearly a decade and have no capacity to test new, critically needed antimicrobials [8] . This latter scenario has led to both preventable spread of resistant pathogens [8, 10] and poor patient outcomes [7] .
Thankfully, some resolution to these issues is in sight. On 13 December 2016, President Obama signed into law the 21st Century Cures Act, which was aimed at facilitating medical product development and innovation through I N V I T E D A R T I C L E streamlining processes that act as hurdles. Section 3044 of law required change to the Federal Food, Drug and Cosmetic Act to create a system that enables and accelerates acceptance of breakpoints and alignment of FDA with a standards development organization (SDO) (ie, CLSI), where data were available to do so [11] . The key provisions of Section 3044 are summarized in Table 1 , and how these address susceptibility test challenges in Table 2 . On 13 December 2017, the FDA launched the Antimicrobial Susceptibility Test Interpretive Criteria (STIC) website [12] , which listed all breakpoints published in current drug labels that included many, but not all, CLSI breakpoints [13] . The law requires the website to be updated at least every 6 months, ensuring a much more timely addition of new or updated CLSI breakpoints. This is a step in the right direction for clinicians, laboratorians, and ultimately for patients, providing not only a common location to house a single set of breakpoints, but also resolving some regulatory paradoxes imposed by the prior system of publishing FDA breakpoints in the drug label [9] , described in detail below. However, several susceptibility testing challenges remain unresolved, which will require continued and coordinated action of many stakeholders to ensure the best methods are available to clinical laboratories and the best results are available to clinicians to combat the rising epidemic of antimicrobial resistance. This commentary will provide an overview of the changes to antimicrobial susceptibility testing driven by the 21st Century Cures Act, its clinical relevance, and remaining unmet needs ( Table 2) . 
Summary of Challenge
Most clinical laboratories in the United States rely on automated cASTs to perform susceptibility testing. Five automated cASTs are cleared by the FDA. The spectrum of organisms and antimicrobials the cASTs are cleared to test is dependent on the device clearance date. Prior to 2007, FDA allowed cASTs manufacturers to obtain clearance for any organism/antimicrobial combination with a breakpoint published by CLSI or in the drug label. However, after this date FDA only allowed cASTs to use breakpoints published in drug labels [14] . In addition, FDA strongly discouraged (prohibited) testing and interpretation of organisms for which the antimicrobial had not been shown to be effective both in vivo and in vitro (ie, off-label organisms), in particular if the organism was biologically distinct or associated with infections different from those indicated in the drug label. For example, trimethoprim-sulfamethoxazole is standard therapy for Stenotrophomonas maltophilia, and yet there are no FDA breakpoints and thus this combination cannot be tested by any cASTs cleared by the FDA after 2007. Many clinicians remain unaffected and unaware of this dilemma because their laboratories use cASTs cleared by the FDA prior to 2007. However, patients are affected in 2 ways that are not immediately evident. First, manufacturers of cASTs are loathe to update their systems for antimicrobial-organism combinations cleared pre-2007, even if they identify issues with the system's ability to identify novel resistance mechanisms. In some cases this is because the cASTs organism list would be narrowed. In other cases, it is because the antimicrobial-organism combination would no longer be allowed to be tested by the cASTs. For example, a manufacturer of a cASTs cleared pre-2007 that identifies a daptomycin test performance issue for Enterococcus faecium could not correct the issue and obtain FDA clearance for the improved test, as treatment of E. faecium is not among the approved clinical indications for daptomycin [15] . Second, novel rapid cASTs are at an intrinsic disadvantage as compared to older competitors, as the menu of organisms and antimicrobials that can be tested must be limited to on-label organisms. As an example, newer diagnostics designed to identify and perform susceptibility testing of A. baumannii are restricted to testing of on-label antimicrobials-that is, the only β-lactams that could be tested are piperacillin-tazobactam, imipenem, and doripenem [16] .
Current Progress and Risks Associated With Addressing Challenge 1
Through the practice of removing breakpoints from drug labels, the 21st Century Cures Act decouples the testing of organisms and the clinical indications for use of an antimicrobial, aligning much more sensibly with the practice of infectious diseases. Although the introduction of the website is a significant first step, for the most part the only breakpoints included on the website are those for which CLSI and FDA were already in alignment. For instance, CLSI breakpoints for A. baumannii are excluded from the list of FDA-recognized CLSI meropenem breakpoints, and the species-specific Candida breakpoints published by CLSI in 2012 are not recognized [12, 17] . Nonetheless, the website now permits cASTs manufacturers to submit data for clearance of off-label members of the Enterobacteriaceae, as Enterobacteriaceae breakpoints on the website are not constrained by which species among the family are indicated for the drug's clinical use.
The FDA has requested data from CLSI to support breakpoints published by CLSI but not yet recognized by FDA (not in current drug labels), and additions to the website are anticipated by mid-2018, with continued additions to be ongoing. However, a major risk to advancement of the website is the lack of recent data to support many older CLSI breakpoints. Several clinically important breakpoints for older agents have recently been evaluated by CLSI [13] and should have sufficient data for FDA endorsement, but many have not been recently evaluated. For example, the S. maltophilia trimethoprim-sulfamethoxazole breakpoint has not been reviewed by CLSI in many years, and it is unlikely that sufficient pharmacokinetic/pharmacodynamic (PK/PD) and clinical outcome data exist to support the current CLSI breakpoint, even though there are no data to suggest this breakpoint is incorrect. CLSI has committed to ongoing and systematic review of all CLSI breakpoints published in document M100 for evidence of the need for revision. However, many of the breakpoints were established before modern PK/ PD approaches were implemented and were based on historical data on clinical outcomes and MIC distributions. It is unknown if these historical data and methodologies will be sufficient for FDA to recognize the breakpoints of older, but still clinically critical, antimicrobials. Because many of these antimicrobials are now generic, it is unlikely a sponsor (pharmaceutical company) will support the studies necessary to generate new data for breakpoint revision. A second, unresolved challenge is how to approach antimicrobial-organism combinations that do not yet have CLSI breakpoints and for which insufficient PK/PD and rigorous clinical data exist to establish a breakpoint. CLSI has recently addressed this challenge through the use of an epidemiological cutoff value (ECV). ECVs distinguish isolates without (wild-type) and with (non-wild-type) resistance mechanisms, by MIC, but do not necessarily predict clinical response. For many years, infectious diseases clinicians have used MIC data for species without a clinical breakpoint, through comparison of the MIC determined by their laboratory to those published in the literature for the same species. The advantage of having an ECV in these cases is not only convenience, but the knowledge that the ECV was defined statistically, using reliable MIC data generated by reference methods. ECVs could be valuable during a deliberation on the risk/benefit of administrating a given antimicrobial, in the absence of well-established clinical breakpoints. At this time, the FDA does not recognize CLSI ECVs on the STIC website and does not currently allow marketing of cASTs for use with ECVs. CLSI advises laboratories to not use ECVs to interpret MIC values as susceptible or resistant in the patient record, despite their potential to inform treatment decisions for a specific patient.
The CLSI ECVs published to date are listed in Table 3 . An example of the clinical and public health utility of an ECV is the drug colistin. CLSI was unable to establish a clinical breakpoint for the Enterobacteriaceae for colistin due to insufficient clinical outcome and PK/PD data. In 2016, the US Centers for Diseases Control and Prevention issued a health advisory recommending isolates of Enterobacteriaceae with colistin MICs >2 µg/mL be screened the presence of mcr [18] . Ironically, FDA prohibits the marketing of cASTs to allow laboratories to test Enterobacteriaceae for susceptibility to colistin, because of the absence of any breakpoints in the colistin drug label. This absence of tests may result in the spread of mcr, undetected. From a clinical perspective, toxicity and often dire clinical scenarios in which colistin is considered for treatment make having MIC data desirable, even without a susceptibility interpretation. Expert consensus is that colistin MICs >2 µg/mL are associated with low likelihood of clinical benefit [19] . One solution to this dilemma is for FDA review and approval of colistin tests as "MIC only, " ensuring that MICs generated by a given cASTs are accurate and precise when compared to CLSIendorsed reference methods (ie, ensure essential agreement). Clearly, alignment between these 2 branches of US government on public health threats and the approach by which to address these is needed.
Challenge 2: Current breakpoints are not available on all cASTs and not uniformly applied by laboratories.
Summary of Challenge
Several organizations publish breakpoints used by laboratories in the United States: the FDA Center for Drug Evaluation and Research, CLSI, the European Committee on Antimicrobial Susceptibility Testing and, most recently, the National Antimicrobial Susceptibility Testing Committee for the United States. No regulations govern which breakpoints clinical laboratories should adopt, but cASTs manufacturers must adhere to FDA-recognized breakpoints for cASTs sold in the United States. However, there is no mechanism to compel these manufacturers to update breakpoints when the FDA-recognized breakpoints change, and as a result not all cASTs have been updated with current breakpoints. In practice, most clinical laboratories rely heavily on cASTs, and until cASTs are FDA cleared for current breakpoints, the laboratory may not change. For instance, 26% of laboratories in California continue to rely on pre-2010 breakpoints to detect carbapenem resistance in Enterobacteriaceae, which is associated with up to 20% false-susceptible results over the updated breakpoints in carbapenemase-producing isolates [8] . Significant patient safety concerns arise when a laboratory cannot provide results for an antimicrobial using the current breakpoints [20] , and this slow adoption of updated breakpoints has likely contributed to inappropriate therapy and the spread of carbapenem-resistant Enterobacteriaceae in the United States.
Current Progress and Risks Associated With Addressing Challenge 2
The provisions of the 21st Century Cures Act include the ability of the FDA to recognize breakpoints established by qualified SDOs (Table 1) and require review and update (when appropriate) of the STIC website at least every 6 months. To date, the only SDO that has submitted to the federal register and met the criteria for FDA recognition is CLSI. CLSI revises breakpoints proactively, in response to resistance or breakpoint issues identified by clinicians and clinical laboratories. Decisions are deliberated and voted on by an open and transparent consensus process. If the decision is deemed scientifically informed by the best data available, FDA can update the breakpoint on the STIC website, and a manufacturer can submit for clearance of their cASTs with the current breakpoint.
While the website now allows cASTs manufacturers to submit their devices for clearance with CLSI breakpoints, there remains no mechanism to compel cASTs manufacturers to update their device for use with the breakpoints listed on the website. 
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A Inevitably, there will be delays as manufacturers evaluate and prioritize updates to their systems to accommodate breakpoints listed on the STIC website. In reality, cASTs manufacturers do not profit from such activities, and they are resource intensive, distracting from development in other areas. Incentives are needed to help support breakpoint-updating activities, akin to those outlined in the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act of 2015, which is designed to support development of cASTs for new drugs and more rapid diagnostic tests. Similarly, once a cASTs is FDA cleared and available, laboratories must perform in-house verification studies, according to US federal regulations, to confirm the system performs as intended by the manufacturer, when used in their own laboratory. Such verification studies include confirmation of the cASTs' accuracy and precision, in addition to quality control testing. Verification studies are resource-intensive for laboratories and often delayed for many years. Further review of the need and methods to support these studies is needed. 
Summary of Challenge
The absence of promptly available, FDA-cleared tests for new antimicrobials to aid in confronting antimicrobial resistance has led to much confusion and frustration on the part of both the laboratory and clinician. This challenge is not necessary and would be solved by coordination among the FDA and pharmaceutical and diagnostic companies.
Current Progress and Risks Associated With Addressing Challenge 3
The 21st Century Cures Act does not address the issue of tests for new antimicrobials. However, much progress has been made since our last commentary [9] on this subject. Traditionally, studies for FDA clearance of a cASTs for a new antimicrobial occurred after that antimicrobial obtained FDA approval. The FDA has drafted guidance for the coordinated development of antimicrobial drugs and cASTs. This guidance outlines the recommended interactions between pharmaceutical companies and cASTs manufacturers. It addresses considerations for submitting an antimicrobial and a cASTs to the FDA in tandem and clarifies that review of the cASTs and antimicrobial remains independent, such that timelines for neither product are adversely affected [21] . Evidence that this process has resulted in a more rapid review and clearance process exists for the antimicrobial delafloxacin, a pilot case for this program. Three cASTs for delafloxacin were cleared by the FDA within 44 days of the drug's approval, and 2 additional devices within 72 and 116 days (Ribhi Shawar, FDA Center for Devices and Radiological Health, personal communication). In contrast, it has historically taken 8 months to 5 years for cASTs to be available for new drugs. While promising, coordinated development requires early close collaboration between pharmaceutical companies, cAST manufacturers, and the FDA. Additionally, all cASTs cleared for delafloxacin are manual tests, whereas most laboratories perform testing using automated instruments. Development of automated cASTs is more complex and time consuming than manual tests and further work toward shortening the time to availability of these is needed. Additional incentives such as those outlined in the READI Act, may aid to expedite this process.
CONCLUSIONS
From the clinician's standpoint, the intricacies of how the laboratory generates the call of "susceptible" vs "resistant" is rarely relevant. However, as resistance increases, there is a growing need to understand the impact of the different and unique roles the FDA, cASTs manufacturers, SDOs, and the laboratory play in arriving at a susceptible vs resistant result. The 21st Century Cures Act begins to deconstruct many of the barriers toward generation of meaningful antimicrobial susceptibility data from the laboratory, thus expediting availability of information to guide appropriate treatment and improving standardization in testing across US laboratories. The law enables more rapid adoption of modern breakpoints and paves the way for new diagnostics to generate rapid and relevant susceptibility data. In some cases, as long as the process is transparent and understood, approval of tests for MICs alone, prior to generation of data to support a clinical breakpoint, could be considered and would be of considerable benefit to both patients and clinicians caring for them. Furthermore, despite these advances, it demands that clinicians develop a better understanding of susceptibility data as an increasing number of "unknowns" remain to be confronted, with new, unproven antimicrobials, organisms, and resistance mechanisms as we all work together to combat the rise in antimicrobial resistance.
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